Clinical trials for medicines: roles and responsibilities
Which professions can act as an investigator, training and experience expectations, provision of medical support and delegation of activities.
Latest change: Survey introduction has been removed as it is out of date.
AI Summary
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has finalized guidance for clinical trials, which became fully effective on April 28, 2026. This regulatory framework is established under the Medicines for Human Use (Clinical Trials) Regulations 2004 and the significant 2025 Amendment Regulations. While the provided text does not identify a specific company, inspection dates, or past violations, it mandates that all trial sponsors and investigators strictly adhere to all relevant official guidance throughout the lifecycle of a trial. According to Part 2 of Schedule 1, the primary requirement is that research parties must demonstrate regard for established standards when commencing and conducting clinical trials. Required actions for stakeholders include ensuring all trial operations are updated to comply with the 2025 amendments, as the guidance is no longer in draft form. This transition signifies that adherence to these standards is now a formal legal expectation for any human clinical research conducted within the United Kingdom, aimed at ensuring participant safety and trial integrity.
The full document, source attachments, and change history are available on KeyPedia. Sign in to view.